Medical Drug Trial That Turned Into A Living Nightmare
Can QSP Save Lives? Lessons from the Bial Trial Debacle
Session 1 – Setting the scene
Cекция биоинформатика: Constructive biotechnologies: the power of mathematical modelling
DSouza 031519 1
BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.